Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 494 participants.
Also called NCT06739044
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 494 participants
- Registry
-
NCT06739044
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06739044. Randomized; no masking; primary purpose treatment. Start 2023-09-20 (actual); primary completion 2024-10-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Ozempic®
- Intervention (Drug)
- HDG1901
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct06739044- Content hash
192cd08dd937536df0c60de0b9e1c870f3c7083925a3dc046e6a441bfdc6bbda